TrialInternational journal of hematology2025
Safety of liposomal daunorubicin-cytarabine (CPX-351) in secondary AML: Japanese phase 1/2 study and global phase 3 study.
Naoko Hosono et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.